Attovia posts positive 12-week Phase 1b ATTO-1310 itch data, plans 2027 Phase 2 trials; IPO lifts cash to $395.9M

On November 9, 2026, Attovia Therapeutics reported Q3 results and a corporate update. It announced positive 12-week Phase 1b topline data for the IL-31 antibody ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. The ATTUNE-CPUO Phase 2 design has been aligned with the FDA, and Phase 2 trials are expected to start in 1H 2027. Cash of about $395.9 million, boosted by an August 2026 IPO, is expected to fund operations into 2030.

09 Nov 2026 · Attovia Therapeutics, Inc. ATTO · Company news

Company's press release (SEC filing): Attovia Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Attovia posts positive 12-week Phase 1b ATTO-1310 itch data, plans 2027 Phase 2 trials; IPO lifts cash to $395.9M

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq